dMed Global/Clinipace Building Bigger Business Than Both
This white paper podcast is part of DIA’s White Paper Library

dMed Global, a full-service clinical contract research organization (CRO) headquartered in China, and Clinipace Incorporated, a full service clinical CRO with US headquarters, announced the merger of the two companies in April 2021. “Western biotech companies increasingly recognize their need for a strategic partner who can stay on the leading edge of fundamental changes in the global clinical landscape,” explains Dr. Lingshi Tan, Founder and Chairman of dMed Global and Global CEO for dMed/Clinipace. “We know that the drug development market in China is growing at greater than 20% a year per annum, and that is almost three times as fast as clinical research in the rest of the world,” says Jason Monteleone, Clinipace CEO who will serve as Chief Business and Strategy Officer for dMed/Clinipace. “We can partner with biotech companies, truly partner with them, be a solutions provider with them, and continue to provide the level of service they would expect out of a mid-size CRO but also bring them the size and scale of a little bit bigger business than both of us combined.”

Lingshi Tan DIA.gif

Lingshi Tan

Global CEO dMed/Clinipace

Jason Monteleone

Chief Business & Strategy Officer
Download Now!

For more information on publishing your White Paper with DIA, including schedule and pricing, please contact Heej Ko at [email protected].